Print Email

Recent Publications by Members of the Neurological Complications Study Group


Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: protocol for a scoping review. Mayo SJ, Kuruvilla J, Laister RC, Ayala AP, Alm M, Byker W, Kelly DL, Saligan L. BMJ Open. 2018 Jan 27;8(1):e017578. Free Article

Distinct and heterogeneous trajectories of self-perceived cognitive impairment among Asian breast cancer survivors. Ng T, Dorajoo SR, Cheung YT, Lam YC, Yeo HL, Shwe M, Gan YX, Foo KM, Loh WK, Koo SL, Jain A, Lee GE, Dent R, Yap YS, Ng R, Chan A. Psychooncology. 2018 Jan 9. [Epub ahead of print]

Chemotherapy-Induced Neuropathy in Cancer Survivors. Miaskowski C, Mastick J, Paul SM, Topp K, Smoot B, Abrams G, et al. J Pain Symptom Manage. 2017 Aug;54(2):204-218.e2.

Chemotherapy-induced neuropathy: Central resolution of a peripherally perceived problem? Cathcart-Rake EJ, Hilliker DR, Loprinzi CL. Cancer. 2017 Jun 1;123(11):1898-1900.

New Practical Approaches to Chemotherapy-Induced Neuropathic Pain: Prevention, Assessment, and Treatment. Majithia N, Loprinzi CL, Smith TJ. Oncology (Williston Park). 2016 Nov 15;30(11).

Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505).  Pachman DR, Qin R, Seisler D, Smith EM, Kaggal S, Novotny P, et al. Support Care Cancer. 2016 Dec;24(12):5059-5068.

Minocycline, a putative neuroprotectant, co-administered with doxorubicin-cyclophosphamide chemotherapy in a xenograft model of triple-negative breast cancer. Himmel LE, Lustberg MB, DeVries AC, Poi M, Chen CS, Kulp SK. Exp Toxicol Pathol. 2016 Oct;68(9):505-515.

Calcium and Magnesium Infusions for the Prevention of Oxaliplatin-Induced Peripheral Neurotoxicity: A Systematic Review. Jordan B, Jahn F, Beckmann J, Unverzagt S, Müller-Tidow C, Jordan K. Oncology. 2016;90(6):299-306.

Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance). Boora GK, Kanwar R, Kulkarni AA, Abyzov A, Sloan J, Ruddy KJ, Banck MS, Loprinzi CL, Beutler AS. Cancer Med. 2016 Apr;5(4):631-9.

National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons. Majithia N, Temkin SM, Ruddy KJ, Beutler AS, Hershman DL, Loprinzi CL. Support Care Cancer. 2016 Mar;24(3):1439-47.

Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies. Reddy SM, Vergo MT, Paice JA, Kwon N, Helenowski IB, Benson AB, et al. Clin Colorectal Cancer. 2016 Mar;15(1):37-46.

Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). Pachman DR, Qin R, Seisler DK, Smith EM, Beutler AS, Ta LE, et al. J Clin Oncol. 2015 Oct 20;33(30):3416-22.

MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. Zimmerman C, Atherton PJ, Pachman D, Seisler D, Wagner-Johnston N, Dakhil S, et al. Support Care Cancer. 2016 Mar;24(3):1071-8.

Can pregabalin prevent paclitaxel-associated neuropathy?--An ACCRU pilot trial.  Shinde SS, Seisler D, Soori G, Atherton PJ, Pachman DR, Lafky J, Ruddy KJ, Loprinzi CL. Support Care Cancer. 2016 Feb;24(2):547-53.

Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance). Boora GK, Kulkarni AA, Kanwar R, Beyerlein P, Qin R, Banck MS, et al. J Neurol Sci. 2015 Oct 15;357(1-2):35-40.

Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study. Cheung YT, Ng T, Shwe M, Ho HK, Foo KM, Cham MT, et al. Ann Oncol. 2015 Jul;26(7):1446-51.

Can pregabalin prevent paclitaxel-associated neuropathy? An ACCRU pilot trial. Shinde SS, Seisler D, Soori G, Atherton PJ, Pachman DR, Lafky J,  et al. Support Care Cancer. 2016 Feb;24(2):547-53.

A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy-associated anemia. Steensma DP, Dakhil SR, Novotny PJ, Sloan JA, Johnson DB, Anderson DM, et al. Am J Hematol. 2015 Oct;90(10):877-81.

Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance). Boora GK, Kulkarni AA, Kanwar R, Beyerlein P, Qin R, Banck MS, Ruddy KJ, et al. J Neurol Sci. 2015 Oct 15;357(1-2):35-40.

Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia. Steensma DP, Sasu BJ, Sloan JA, Tomita DK, Loprinzi CL. Blood. 2015 Jun 4;125(23):3669-71.

Neuropathic symptoms and their risk factors in medical oncology outpatients with colorectal vs. breast, lung, or prostate cancer: Results from a prospective multicenter study. Lewis MA, Zhao F, Jones D, Loprinzi CL, Brell J, Weiss M, Fisch MJ. J Pain Symptom Manage. 2015 Jun;49(6):1016-24.

Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Ewertz M, Qvortrup C, Eckhoff L.  Acta Oncol. 2015 May;54(5):587-91.

Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy. Pachman DR, Weisbrod BL, Seisler DK, Barton DL, Fee-Schroeder KC, Smith TJ et al. Support Care Cancer. 2015 Apr;23(4):943-51.

Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy. Pachman DR, Weisbrod BL, Seisler DK, Barton DL, Fee-Schroeder KC, Smith TJ, et al. Support Care Cancer. 2015 Apr;23(4):943-51.

Docetaxel-induced neuropathy: a pharmacogenetic case-control study of 150 women with early-stage breast cancer. Eckhoff L, Feddersen S, Knoop AS, Ewertz M, Bergmann TK.  Acta Oncol. 2015 Apr;54(4):530-7.

Systematic review of pharmacologic and non-pharmacologic interventions to manage cognitive alterations after chemotherapy for breast cancer. Chan RJ, McCarthy AL, Devenish J, Sullivan KA, Chan A. Eur J Cancer. 2015 Mar;51(4):437-50.

Neuropathic symptoms, quality of life, and clinician perception of patient care in medical oncology outpatients with colorectal, breast, lung, and prostate cancer. Jones D, Zhao F, Brell J, Lewis MA, Loprinzi CL, Weiss M, Fisch MJ. J Cancer Surviv. 2015 Mar;9(1):1-10.

Chemotherapy-induced neuropathy—Where are we now? Ruddy, KJ, Majithia, N, Pachman DR, Beutler AS, Loprinzi CL. Oncology & Hematology Review, Spring 2015;11(1):53–5.

Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors. Eckhoff L, Knoop A, Jensen M, Ewertz M.  Eur J Cancer. 2015 Feb;51(3):292-300.

Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients. Johnson C, Pankratz VS, Velazquez AI, Aakre JA, Loprinzi CL, Staff NP, Windebank AJ, Yang P.  J Neurol Sci. 2015 Feb 15;349(1-2):124-8.

The genetic variants underlying breast cancer treatment-induced chronic and late toxicities: a systematic review. Ng T, Khor CC, Ho HK, Chan A.  Cancer Treatment Reviews 2014; Dec;40(10):1199-1214.

Therapeutic strategies for cancer treatment related peripheral neuropathies. Pachman DR, Watson JC, Loprinzi CL. Curr Treat Options Oncol. 2014 Dec;15(4):567-80.

Docetaxel-induced neuropathy: A pharmacogenetic case-control study of 150 women with early-stage breast cancer. Eckhoff L, Feddersen S, Knoop AS, Ewertz M, Bergmann TK.  Acta Oncol. 2014 Nov 10:1-8.

Management options for established chemotherapy-induced peripheral neuropathy. Pachman DR, Watson JC, Lustberg MB, Wagner-Johnston ND, Chan A, Broadfield L, et al. Support Care Cancer. 2014 Aug;22(8):2281-95.

Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: cognitive function (FACT-Cog) in breast cancer patients. Cheung YT, Foo YL, Shwe M, Tan YP, Fan G, Yong WS, et al. J Clin Epidemiology 2014; Jul;67(7):811-20.

North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study.  Leal AD, Qin R, Atherton PJ, Haluska P, Behrens RJ, Tiber CH, Watanaboonyakhet P, Weiss M, Adams PT, Dockter TJ, Loprinzi CL; Alliance for Clinical Trials in Oncology.Cancer. 2014 Jun 15;120(12):1890-7.

Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, et al. J Clin Oncol. 2014 Apr 1;32(10):997-1005.